At 21.7% CAGR, Europe Cell and Gene Therapy Market is Projected to be Worth US$ 5,334.44 Million by 2031, says Business Market Insights

According to Business Market Insights' research, the Europe cell and gene therapy market was valued at US$ 1,105.10 million in 2023 and is projected to reach US$ 5,334.44 million by 2031, registering a CAGR of 21.7% from 2023 to 2031. Strategic initiatives by companies and increase in number of approvals of cell and gene therapies are among the critical factors attributed to drive the Europe cell and gene therapy market growth.

Many companies involved in manufacturing cell and gene therapy products focus on collaborations, expansions, agreements, partnerships, new product launches, and other strategic developments. These strategic initiatives help them improve sales, expand geographic reach, and enhance capacities to cater to a large customer base. A few of the significant developments in the cell and gene therapy market are mentioned as; In March 2022, Cellevolve Bio partnered with Seattle Children's Therapeutics to develop and commercialize new multiplex CARs for pediatric cancers. With this collaboration, the companies will focus on the BrainChild research program-a suite of five multiplex CARs-to treat pediatric central nervous system (CNS) malignancies. They aim to leverage the Seattle Children's Cure Factory facility to conduct early clinical GMP research on new CARs. In March 2022, Twist Bioscience Corporation and Kriya Therapeutics, Inc. entered an antibody discovery agreement for antibodies delivered using adeno-associated viral (AAV) gene therapy in therapeutic oncology applications. Also, the companies aim to combine Twist's antibody libraries with Kriya's proprietary vector engineering platform to discover novel antibodies against specific targets of interest to be delivered with Kriya's gene therapy technology. In January 2022, FUJIFILM Corporation agreed to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. The facility will witness expansion with the flexibility to produce clinical as well as commercial cell therapies, such as allogeneic T-cell and CAR T immunotherapies. In January 2021, Thermo Fisher Scientific Inc. acquired Henogen S.A., the viral vector manufacturing business of Groupe Novasep SAS in Belgium. Henogen offers vaccine and therapeutics manufacturing services to biotechnology companies and a few biopharmaceutical customers. Through this acquisition, Thermo Fisher Scientific expanded its capabilities in the category of cell and gene vaccines and therapies. The initiation of new businesses to remain competitive in the market through collaborations and partnerships can help accelerate the development of new platforms for cell and gene therapy manufacturing services. Thus, these strategic initiatives by key players are anticipated to create substantial growth opportunities in the cell and gene therapy market during the forecast period.

On the contrary, high cost of cell and gene therapy manufacturing hampers the growth of Europe cell and gene therapy market.

Based on type, the Europe cell and gene therapy market is bifurcated into cell therapy and gene therapy. The cell therapy segment held 66.2% market share in 2023, amassing US$ 731.30 million. It is projected to garner US$ 3,814.50 million by 2031 to register 22.9% CAGR during 2023-2031. Furthermore, the cell therapy segment is subcategorized into allogeneic, autologous, viral vectors. Additionally, the gene therapy segment is bifurcated into non-viral vectors and viral vectors.

In terms of services, the Europe cell and gene therapy market is segmented into process development, cGMP manufacturing, regulatory services, and bioassay services. The process development segment held 42.1% share of Europe cell and gene therapy market in 2023, amassing US$ 465.19 million. It is anticipated to garner US$ 2,610.42 million by 2031 to expand at 24.1% CAGR during 2023-2031.

By scale, the Europe cell and gene therapy market is divided into pre-commercial/ R and D manufacturing and commercial scale manufacturing. The pre-commercial/ R and D manufacturing segment held 64.6% share of Europe cell and gene therapy market in 2023, amassing US$ 713.51 million. It is projected to garner US$ 3,632.62 million by 2031 to expand at 22.6% CAGR from 2023 to 2031.

By end user, the Europe cell and gene therapy market is segmented into contract research organizations, pharmaceutical and biopharmaceutical companies, and academic and research institutes. The pharmaceutical and biopharmaceutical companies segment held 50.3% share of Europe cell and gene therapy market in 2023, amassing US$ 555.98 million. It is estimated to garner US$ 2,476.94 million by 2031 to expand at 20.5% CAGR during 2023-2031.

Based on country, the Europe cell and gene therapy market is categorized into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Our regional analysis states that Germany captured 20.4% share of Europe cell and gene therapy market in 2023. It was assessed at US$ 225.00 million in 2023 and is likely to hit US$ 1,207.63 million by 2031, registering a CAGR of 23.4% during 2023-2031.

Key players operating in the Europe cell and gene therapy market are Catalent Inc, Cell and Gene Therapy Catapult, Charles River Laboratories International Inc, F. Hoffmann-La Roche Ltd, FUJIFILM Holdings Corp, Lonza Group AG, Lotte Corp, Merck KGaA, Takara Bio Inc, Thermo Fisher Scientific Inc., and WuXi AppTec Co Ltd, among others.

• In February 2024, Novo Holdings has entered an agreement to acquire Catalent, Inc. under which Novo Holdings will acquire Catalent in an all-cash transaction that values Catalent at $16.5 billion on an enterprise value basis.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com